Drug Database
Back to search

Switzerland· 34914002

Lampren 100 mg, Kapseln

A clofazimine product, registered in Switzerland by Novartis Pharma Schweiz AG and dispensed under Swissmedic category B. The same ATC class is registered in 7 of our 19 countries.

Cat B (Swissmedic)ATC J04BA01

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · CHPublic registernormalisedLampren 100 mg, KapselnATCJ04BA01REGISTER NO.34914002PACKS LISTED0CHECKEDJune 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about LamprenAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Clofazimine is registered in 7 of 19 countries.

Countries holding a registration under ATC J04BA01 (clofazimine), each read from that country’s own register.

  • This record: Switzerland
  • 5 of them publish a price we can compare per daily dose
Search clofazimine products by name

Clofazimine · ATC J04BA01

7 / 19 countries

  • Czechiaprice
  • Franceprice
  • Japan
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Manufacturer
Novartis Pharma Schweiz AG
Country
Switzerland (CH)
ATC code
J04BA01
ATC class
Clofazimine
Defined daily dose
0.1 g, O
Swissmedic category
B
Reimbursed
No
Last checked
June 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

158 interactions on record for clofazimine.

Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check clofazimine against other medicinesHow interaction checks work

Clofazimine · interactions on record

158 records

  • 37 severe
  • 119 moderate
  • 2 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under J04BA01

Clofazimine, as other registers publish it.

All clofazimine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/937238d7-6c8a-4d24-b570-8f856eeb82ee
GET /v1/drugs/937238d7-6c8a-4d24-b570-8f856eeb82ee?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "swissmedic_auth",
  "heilmittelcode": "Synthetika"
}
API referenceMCP serverPlans

See everything about clofazimine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console